← 返回

靶向肿瘤浸润性 CCR8(+) 调节性 T 细胞通过功能性恢复结直肠癌中的 CD4(+) 常规 T 细胞和 CD8(+)T 细胞诱导抗肿瘤免疫

英文原题:Targeting tumor-infiltrating CCR8(+) regulatory T cells induces antitumor immunity through functional restoration of CD4(+) T(convs) and CD8(+) T cells in colorectal cancer.

查看英文原题

Targeting tumor-infiltrating CCR8(+) regulatory T cells induces antitumor immunity through functional restoration of CD4(+) T(convs) and CD8(+) T cells in colorectal cancer.

PubMed 2024/07/30(内容时间) J Transl Med Q1 · IF 9.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

这些发现说明了 CCR8+ Tregs 通过功能性抑制 CD4+ T convs 和 CD8+ T 细胞,对 CRC 肿瘤免疫抑制微环境的重要性,并提示了 CCR8 靶向治疗在 CRC 中的适用价值。

研究思路结论见上方概要

趋化因子(C-C基序)受体8(CCR8)是一种选择性表达于肿瘤浸润性调节性T细胞(Tregs)上的趋化因子受体。在乳腺和肺部恶性肿瘤中观察到的CCR8+ Tregs介导的强免疫抑制表明其在癌症治疗中具有功能意义。迄今为止,关于结直肠癌(CRC)中肿瘤浸润性CCR8+ Tregs细胞的详细特征描述仍然有限。

为研究CCR8 + Tregs在CRC中的存在及功能参与,我们通过流式细胞术分析了CRC患者肿瘤组织、癌旁正常组织和外周血单个核细胞(PBMCs)中不同T细胞亚群表达CCR8的T细胞比例。同时,我们比较了皮下CRC小鼠模型中CCR8 + T细胞在恶性组织和外周淋巴器官中的分布。进行生物信息学分析,以探讨CCR8表达水平在CRC预后、免疫调节基因表达谱以及CRC肿瘤中CCR8 + Tregs相关潜在分子机制中的意义。进一步,我们向CT26荷瘤小鼠施用了抗CCR8单克隆抗体,并在体内和离体验证模型中检测了CCR8靶向治疗的反肿瘤活性。

在这里,我们展示了Tregs主要存在于CRC患者的肿瘤中(13.4 ± 5.8,p < 0.0001)以及CRC皮下小鼠模型中(35.0 ± 2.6,p < 0.0001)。发现CCR8优先表达于这些肿瘤浸润性Tregs上(CRC患者:63.6 ± 16.0,p < 0.0001;CRC小鼠模型:65.3 ± 9.5,p < 0.0001),这与较差的生存率相关。我们发现大多数CCR8 + Tregs表达活化标志物并表现出强烈的抑制功能。使用抗CCR8抗体治疗通过有效恢复CD4 +常规T细胞(CD4 + T convs)和CD8 + T细胞的抗肿瘤免疫,抑制了皮下CRC肿瘤的生长,这在离体检查中得到了证实。

展开英文摘要原文

Chemokine (C-C motif) receptor 8 (CCR8) is a chemokine receptor selectively expressed on tumor-infiltrating regulatory T cells (Tregs). Strong immunosuppression mediated by CCR8 + Tregs observed in breast and lung malignancies suggest for their functional significance in cancer therapy. To date, detailed characterization of tumor-infiltrating CCR8 + Tregs cells in colorectal cancer (CRC) is limited.

To study the presence and functional involvement of CCR8 + Tregs in CRC, we analyzed the proportions of CCR8-expressing T cells in different T cell subsets in tumor and adjacent normal tissues and peripheral blood mononuclear cells (PBMCs) from CRC patients by Flow cytometry. Also, we compared the distribution of CCR8 + T cells in malignant tissues and peripheral lymphoid organs from a subcutaneous CRC murine model. Bioinformatic analysis was performed to address the significance of CCR8 expression levels in CRC prognosis, immune regulatory gene expression profiles and potential molecular mechanisms associated with CCR8 + Tregs in CRC tumors. Further, we administrated an anti-CCR8 monoclonal antibody to CT26 tumor-bearing mice and examined the antitumor activity of CCR8-targeted therapy both in vivo and in an ex vivo confirmative model.

Here, we showed that Tregs was predominantly presented in the tumors of CRC patients (13.4 ± 5.8, p < 0.0001) and the CRC subcutaneous murine model (35.0 ± 2.6, p < 0.0001). CCR8 was found to be preferentially expressed on these tumor-infiltrating Tregs (CRC patients: 63.6 ± 16.0, p < 0.0001; CRC murine model: 65.3 ± 9.5, p < 0.0001), which correlated with poor survival. We found that majority of the CCR8 + Tregs expressed activation markers and exhibited strong suppressive functions. Treatment with anti-CCR8 antibody hampered the growth of subcutaneous CRC tumor through effectively restoring the anti-tumor immunity of CD4 + conventional T cells (CD4 + T convs ) and CD8 + T cells, which was confirmed in the ex vivo examinations.

Collectively, these findings illustrate the importance of CCR8 + Tregs for an immunosuppressive microenvironment in CRC tumors by functional inhibition of CD4 + T convs and CD8 + T cells, and suggest for the applicable value of CCR8-targeted therapy for CRC.

论文信息

作者
Chen Q、Shen M、Yan M、Han X、Mu S、Li Y、Li L、Wang Y
第一作者单位
Department of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.China
通讯作者单位
Department of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China. aishunjin@cqmu.edu.cn.China
文献类型
非美国政府资助研究
期刊
Journal of translational medicine2024 Jul 30
原文标识
PubMed 39080766 · DOI 10.1186/s12967-024-05518-8